Birchview Capital, LP Buys Harrow Health Inc, Bristol-Myers Squibb Company, Dermira Inc, Sells Clementia Pharmaceuticals Inc, Harrow Health Inc, Harrow Health Inc

• New Purchases: HROW, ACAD, APLS, MREO, BCRX,
• Added Positions: BMY, DERM, VRML, OXFD, GTHX, BIIB, IMGN, QDEL,
• Reduced Positions: ATRA, VCYT,
• Sold Out: CMTA, 3IP, 3IP, IFRX, OMED, SITO,

For the details of Birchview Capital, LP's stock buys and sells, go to https://www.gurufocus.com/guru/birchview+capital%2C+lp/current-portfolio/portfolioportfolio

1. Celgene Corp (CELG) - 697,667 shares, 39.41% of the total portfolio. Shares reduced by 0.19%
2. Accelerate Diagnostics Inc (AXDX) - 2,183,795 shares, 30.53% of the total portfolio.
3. Array BioPharma Inc (ARRY) - 168,000 shares, 4.76% of the total portfolio.
4. Neurocrine Biosciences Inc (NBIX) - 55,000 shares, 2.84% of the total portfolio.
5. Quidel Corp (QDEL) - 48,844 shares, 1.77% of the total portfolio. Shares added by 3.76%

Birchview Capital, LP initiated holding in Harrow Health Inc. The purchase prices were between $4.2 and $8.7, with an estimated average price of $5.51. The stock is now traded at around $6.95. The impact to a portfolio due to this purchase was 0.96%. The holding were 180,000 shares as of .

Birchview Capital, LP initiated holding in ACADIA Pharmaceuticals Inc. The purchase prices were between $23.32 and $28.12, with an estimated average price of $25.52. The stock is now traded at around $28.52. The impact to a portfolio due to this purchase was 0.16%. The holding were 10,000 shares as of .

Birchview Capital, LP initiated holding in Apellis Pharmaceuticals Inc. The purchase prices were between $18 and $25.34, with an estimated average price of $20.3. The stock is now traded at around $25.98. The impact to a portfolio due to this purchase was 0.12%. The holding were 8,000 shares as of .

Birchview Capital, LP initiated holding in Mereo BioPharma Group PLC. The purchase prices were between $2.52 and $6.5, with an estimated average price of $4.38. The stock is now traded at around $2.71. The impact to a portfolio due to this purchase was 0.07%. The holding were 47,570 shares as of .

Birchview Capital, LP initiated holding in Biocryst Pharmaceuticals Inc. The purchase prices were between $2.91 and $9.15, with an estimated average price of $6.01. The stock is now traded at around $2.88. The impact to a portfolio due to this purchase was 0.05%. The holding were 20,000 shares as of .

Birchview Capital, LP added to a holding in Bristol-Myers Squibb Company by 120.00%. The purchase prices were between $44.62 and $49.34, with an estimated average price of $46.57. The stock is now traded at around $45.12. The impact to a portfolio due to this purchase was 0.67%. The holding were 44,000 shares as of .

Birchview Capital, LP added to a holding in Dermira Inc by 500.00%. The purchase prices were between $8.91 and $14.82, with an estimated average price of $10.77. The stock is now traded at around $7.81. The impact to a portfolio due to this purchase was 0.58%. The holding were 120,000 shares as of .

Birchview Capital, LP added to a holding in Vermillion Inc by 47.13%. The purchase prices were between $0.87 and $1.44, with an estimated average price of $1.16. The stock is now traded at around $0.65. The impact to a portfolio due to this purchase was 0.54%. The holding were 3,121,933 shares as of .

Birchview Capital, LP added to a holding in Oxford Immunotec Global PLC by 74.72%. The purchase prices were between $13.42 and $16.62, with an estimated average price of $15.29. The stock is now traded at around $14.25. The impact to a portfolio due to this purchase was 0.5%. The holding were 140,303 shares as of .

Birchview Capital, LP added to a holding in G1 Therapeutics Inc by 166.67%. The purchase prices were between $16.03 and $31.1, with an estimated average price of $21.03. The stock is now traded at around $23.58. The impact to a portfolio due to this purchase was 0.47%. The holding were 40,000 shares as of .

Birchview Capital, LP added to a holding in Biogen Inc by 100.00%. The purchase prices were between $219.29 and $241.72, with an estimated average price of $230.78. The stock is now traded at around $235.87. The impact to a portfolio due to this purchase was 0.36%. The holding were 5,000 shares as of .

Birchview Capital, LP sold out a holding in Clementia Pharmaceuticals Inc. The sale prices were between $25.95 and $26.49, with an estimated average price of $26.23.

Birchview Capital, LP sold out a holding in Harrow Health Inc. The sale prices were between $3.62 and $7.11, with an estimated average price of $4.76.

Birchview Capital, LP sold out a holding in Harrow Health Inc. The sale prices were between $3.62 and $7.11, with an estimated average price of $4.76.

Birchview Capital, LP sold out a holding in InflaRx NV. The sale prices were between $3.06 and $51.61, with an estimated average price of $31.98.

Birchview Capital, LP sold out a holding in OncoMed Pharmaceuticals Inc. The sale prices were between $0.89 and $1.16, with an estimated average price of $1.01.

Birchview Capital, LP sold out a holding in SITO Mobile Ltd. The sale prices were between $0.67 and $2.14, with an estimated average price of $1.38.